COAPT Risk Score: A Comprehensive Risk Prediction Tool for Severe Functional Mitral Regurgitation

The COAPT Risk Score is an innovative and clinically significant calculator designed to assess the two-year risk of mortality and/or heart failure hospitalization (HFH) in patients suffering from severe functional mitral regurgitation (FMR) and symptomatic heart failure. This tool is specifically intended for educational purposes and use by healthcare professionals, particularly those specializing in cardiology. It caters to individuals with left ventricular ejection fractions ranging between 20% and 50%, who continue to experience symptoms despite receiving optimal guideline-directed medical therapy (GDMT).

The development of the COAPT Risk Score marks a pivotal advancement in predicting patient outcomes for those afflicted with heart failure and severe FMR. The score is derived from data collected during the COAPT trial, a landmark study involving patients with heart failure and moderate-to-severe or severe FMR. These participants were randomized into two groups: one receiving transcatheter edge-to-edge repair (TEER) with MitraClip in addition to GDMT, and the other receiving GDMT alone. By integrating both clinical and echocardiographic variables, the COAPT Risk Score offers critical insights into prognostic indicators, empowering clinicians to make informed decisions tailored to individual patient needs.

The primary utility of the COAPT Risk Score lies in its ability to serve as a shared decision-making tool for both patients and their healthcare providers. As TEER becomes increasingly integrated into clinical practice, this score provides updated predictions of two-year risks, enabling more precise discussions around treatment options. Whether used independently or in conjunction with TEER, the COAPT Risk Score acts as a cornerstone for comprehensive care planning.

The creation of the COAPT Risk Score is the result of collaboration among a distinguished group of experts. Led by Dr. Kini, the director of The Mount Sinai Hospital cardiac catheterization laboratory, the team also includes Dr. Sharma, the Director of Clinical and Interventional Cardiology at the Mount Sinai Health System, Dr. Tang, the Surgical Director at The Mount Sinai Hospital, Dr. Stone, the principal investigator of the COAPT trial, and Dr. Shah, the author of the publication detailing the risk score. Together, these specialists have crafted a tool that not only reflects cutting-edge research but also addresses real-world clinical challenges.

In summary, the COAPT Risk Score represents a vital resource for cardiologists and related professionals working with complex cases involving severe FMR and heart failure. Its integration into clinical workflows facilitates better communication between doctors and patients, ultimately improving outcomes through personalized care plans. This tool underscores the importance of evidence-based medicine and collaborative expertise in advancing cardiovascular health.